Assembly Biosciences
Professor Stephan Urban is head of the Translational Virology unit at the Department of Infectious Diseases, Molecular Virology at Heidelberg University Hospital. He completed his Diploma in Biochemistry at the University of Tübingen in 1991 and was awarded a Ph.D. in 1995 under Prof. Dr. P.H. Hofschneider at the Max-Planck-Institut for biochemistry, Martinsried. He undertook his postdoctoral research at the Centre for Molecular Biology (ZMBH), Heidelberg University with Prof. Dr. H. Schaller. Between 2008 and 2012 he was a project leader of the BMBF-network "Innovative therapies” and since 2011 he is coordinator in the hepatitis unit of the German Centre for Infection Research (DZIF).
Professor Urban’s research interests include molecular mechanisms of Hepatitis B- and Hepatitis D Virus/host interactions with a focus on the early and late events of viral infection; identification of hepadnaviral receptors and structural analyses of virus receptor interactions; development of novel cell culture systems and animal models for HBV and HDV; clinical development of entry inhibitors for HBV and HDV infection; development of hepatotropic drugs for the therapy of liver diseases; development of diagnostic tools for chronic hepatitis D.
This person is not in the org chart
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.